Products for Research Use Only

Darexaban

CAT: 0804-HY-14853-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14853-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects[1][2][3].
CAS Number
365462-23-3
Product Name Alternative
YM150
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Factor Xa; Ser/Thr Protease
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/darexaban.html
Purity
98.05
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(NC1=C(NC(C2=CC=C(OC)C=C2)=O)C=CC=C1O)C3=CC=C(N4CCN(C)CCC4)C=C3
Molecular Formula
C27H30N4O4
Molecular Weight
474.55
Precautions
H302, H315, H319, H335
References & Citations
[1]Fukushi Hirayama, et al. Discovery of N-[2-hydroxy-6- (4-methoxybenzamido) phenyl]-4- (4-methyl-1,4-diazepan-1-yl) benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. J Med Chem. 2011 Dec 8;54 (23) :8051-65.|[2]Seiji Kaku, et al. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. Thromb Res. 2013 May;131 (5) :450-6.|[3]Milan Remko, et al. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21 (2) :185.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3